Feldan Therapeutics Completes a US$ 21 Million Series B Financing

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Feldan Therapeutics, a biopharmaceutical company specializing in the development of treatments based on intracellular delivery of therapeutics, recently announced the closure of a US$ 21 million Series B round co-led by Genesys Capital (Genesys) and Fonds de solidarité FTQ (Fonds).

The proceeds will be used to complete a Phase 1/2a study for FLD-103 – a first-in-class non-invasive intralesional treatment for basal cell carcinoma (“BCC”) designed to provide an alternative treatment to surgery.

Feldan Therapeutics presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Canadian Medical Technology Consortium Collaborates on State-of-the-Art Postoperative Patient Management Platform, Led by FluidAI
Next

Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy